

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Eprecis 20 mg/ml solution for injection for cattle, sheep and goats

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

**Active substance:**

Eprinomectin 20.0 mg

**Excipients:**

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Butylhydroxytoluene (E321)	0.8 mg
Dimethyl sulfoxide	
Glycerol formal stabilised	

Clear colourless to pale yellow solution.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Cattle, sheep and goats.

#### **3.2 Indications for use for each target species**

Treatment of infestations by the following internal and external parasites sensitive to eprinomectin:

**Cattle**

	Adult	L4	Inhibited L4
<b>Gastrointestinal roundworms</b>			
<i>Ostertagia ostertagi</i>	•	•	•
<i>Ostertagia lyrata</i>	•		
<i>Ostertagia</i> spp.	•	•	
<i>Cooperia oncophora</i>	•	•	
<i>Cooperia pectinata</i>	•	•	
<i>Cooperia surnabada</i>	•	•	
<i>Cooperia punctata</i>	•	•	
<i>Cooperia</i> spp.	•	•	•

<i>Haemonchus placei</i>	•	•	
<i>Trichostrongylus axei</i>	•	•	
<i>Trichostrongylus colubriformis</i>	•	•	
<i>Trichostrongylus</i> spp.	•	•	
<i>Bunostomum phlebotomum</i>	•	•	
<i>Nematodirus helvetianus</i>	•	•	
<i>Oesophagostomum radiatum</i>	•	•	
<i>Oesophagostomum</i> spp.	•		
<i>Trichuris</i> spp.	•		
<b>Lungworms</b>			
<i>Dictyocaulus viviparus</i>	•	•	

**Sucking lice:** *Haematopinus eurysternus*, *Linognathus vituli*, *Solenopotes capillatus*

**Horn flies:** *Haematobia irritans*

**Warbles** (parasitic stages): *Hypoderma bovis*, *Hypoderma lineatum*

**Mange mites:** *Sarcoptes scabiei* var. *bovis*

#### Prevention of reinfestations:

- *Trichostrongylus* spp. (including *Trichostrongylus axei* and *Trichostrongylus colubriformis*), *Haemonchus placei*, *Cooperia* spp. (including *Cooperia oncophora*, *Cooperia punctata*, *Cooperia surnabada*), *Dictyocaulus viviparus*, *Oesophagostomum radiatum*, *Ostertagia* spp. (including *Ostertagia ostertagi* and *Ostertagia lyrata*) and *Nematodirus helvetianus* for 14 days.
- *Haematobia irritans* for at least 7 days.

#### Sheep

##### **Gastrointestinal roundworms (adult)**

*Teladorsagia circumcincta* (pinnata/trifurcata),

*Haemonchus contortus*

*Trichostrongylus axei*

*Trichostrongylus colubriformis*

*Nematodirus battus*

*Cooperia curticei*

*Chabertia ovina*

*Oesophagostomum venulosum*

##### **Lungworm (adult)**

*Dictyocaulus filaria*

##### **Nasal bots (L1, L2, L3)**

*Oestrus ovis*

#### Goats

##### **Gastrointestinal roundworms (adult)**

*Teladorsagia circumcincta* (pinnata/trifurcata)

*Haemonchus contortus*

*Trichostrongylus axei*

*Trichostrongylus colubriformis*  
*Nematodirus battus*  
*Cooperia curticei*  
*Oesophagostomum venulosum*

**Lungworm (adult)**

*Dictyocaulus filaria*

**Nasal bots (L1, L2, L3)**

*Oestrus ovis*

**3.3 Contraindications**

Do not use in other species; avermectins can cause fatalities in dogs, especially Collies, Old English Sheepdogs and related breeds and crosses, and also in turtles/tortoises.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not administer orally or by intramuscular or by intravenous injection.

**3.4 Special warnings**

Cattle, sheep and goats

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on confirmation of the parasitic species and burden, or of the risk of based on its epidemiological features, for each herd/flock.

Repeated use for an extended period, particularly when using the same class of substances, increases the risk of resistance development. Within a herd/flock, maintenance of susceptible refugia is essential to reduce that risk. Systematically applied interval-based treatment and treatment of a whole herd/flock should be avoided. Instead, if feasible, only selected individual animals or subgroups should be treated (targeted selective treatment). This should be combined with appropriate husbandry and pasture management measures. Guidance for each specific herd/flock should be sought from the responsible veterinarian.

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

Confirmed resistance should be reported to the marketing authorisation holder or to the competent authorities.

If there is a risk for re-infection, the advice of a veterinarian should be sought regarding the need for and frequency of repeat administration.

### Cattle

Resistance to other macrocyclic lactones has been reported in parasite species in cattle within the EU. Therefore, use of this veterinary medicinal product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

### Sheep and goats

Resistance to eprinomectin in parasite species in goats and sheep has been reported within the EU. Therefore, use of this veterinary medicinal product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

## **3.5 Special precautions for use**

### Special precautions for safe use in the target species

Usual aseptic procedures for administration of a parenteral injection should be followed.

The death of warble fly larvae in the oesophagus or spinal cord canal may lead to secondary reactions. In order to avoid secondary reactions due to the death of Hypoderma larvae in the oesophagus or the spine, it is recommended to administer the veterinary medicinal product at the end of the period of fly activity and before the larvae reach their resting site.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to eprinomectin or to any of the excipients should avoid contact with the veterinary medicinal product

The veterinary medicinal product causes serious eye irritation. Avoid contact with the eyes. Wash any splashes from eyes immediately with water.

This veterinary medicinal product may cause neurotoxicity. Care should be taken when handling the veterinary medicinal product to avoid self-injection. In case of accidental injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Avoid contact with the skin. Wash any splashes from skin immediately with water.

Avoid oral exposure. Do not eat, drink or smoke while handling the veterinary medicinal product.

Wash hands after use.

The excipient glycerol formal may cause harm to the unborn child. In addition, the active substance eprinomectin can be transferred to breast milk. Pregnant/breast-feeding women and women of childbearing age should therefore avoid exposure to this veterinary medicinal product.

### Special precautions for the protection of the environment:

Eprinomectin is very toxic to dung fauna and aquatic organisms, is persistent in soils and may accumulate in sediments.

The risk to aquatic ecosystems and dung fauna can be reduced by avoiding too frequent and repeated use of eprinomectin (and products of the same anthelmintic class) in cattle, sheep and goats.

The risk to aquatic ecosystems will be further reduced by keeping treated cattle, sheep and goats away from water bodies for two to five weeks after treatment.

### 3.6 Adverse events

#### - Cattle:

Very common (>1 animal / 10 animals treated):	Injection site swelling <sup>1</sup> , Injection site pain <sup>2</sup>
--------------------------------------------------	-------------------------------------------------------------------------

<sup>1</sup> Moderate to severe, typically resolves within 7 days but induration may persist for in excess of 21 days.

<sup>2</sup> Mild to moderate this reaction disappears without any treatment and does not impair the safety or efficacy of the veterinary medicinal product.

#### - Sheep and goats:

Very common (>1 animal / 10 animals treated):	Injection site swelling <sup>1</sup> Immediate pain upon injection <sup>2</sup>
--------------------------------------------------	------------------------------------------------------------------------------------

<sup>1</sup> Slight to moderate, typically resolves within 16 to 18 days

<sup>2</sup> Manifested by head movements and discomfort in sheep.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system.  
See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

#### Cattle:

Can be used during pregnancy and lactation.

#### Sheep and goats:

The safety of eprinomectin during pregnancy in sheep and goats has not been tested. Use only according to the benefit/risk assessment of the responsible veterinarian in these species.

### 3.8 Interaction with other medicinal products and other forms of interaction

Since eprinomectin binds strongly to plasma proteins, this should be taken into account if it is used in association with other molecules having the same characteristics.

### 3.9 Administration routes and dosage

Subcutaneous use. For single administration only.

Administration of 0.2 mg of eprinomectin per kg bodyweight; corresponding to 0.1ml of the veterinary medicinal product per 10 kg bodyweight.

In goats, the volume per injection site should not exceed 0.6 ml.

50 ml and 100 ml vials

Do not exceed 30 broachings per vial. If more than 30 broachings are required, use of a draw off needle is recommended.

250 ml and 500 ml vials

Do not exceed 20 broachings per vial. If more than 20 broachings are required, use of a draw off needle is recommended.

Underdosing could result in ineffective use and may favour resistance development. To ensure a correct dosage, body weight should be determined as accurately as possible. If animals are to be treated collectively, reasonably homogeneous groups should be set up, and all animals of a group should be dosed at the rate corresponding to the heaviest one. Accuracy of the dosing device should be thoroughly checked.

**3.10 Symptoms of overdose (and where applicable, emergency procedures, and antidotes)**

Cattle, sheep:

After subcutaneous administration of up to 5 times the recommended dose, no adverse events were observed except a transient reaction (swelling followed by induration) at the injection site.

The safety of the veterinary medicinal product in goats has not been demonstrated in overdose studies.

**3.11. Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

**3.12 Withdrawal periods**

Cattle:

- Meat and offal: 63 days
- Milk: zero hours.

Sheep:

- Meat and offal: 42 days
- Milk: zero hours.

Goats:

- Meat and offal: 42 days
- Milk: zero hours.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATC vet code:**

QP54AA04

### **4.2 Pharmacodynamics**

Eprinomectin is a member of the macrocyclic lactone class of endectocides. Compounds of the class bind selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve or muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite.

Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA).

The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels; the macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels, and they do not readily cross the blood-brain barrier.

### **4.3 Pharmacokinetics**

#### Absorption

In cattle, following subcutaneous administration, the bioavailability of eprinomectin is about 89%. The maximal mean plasma concentration of 58 µg/L was reached after 36-48 h.

In lactating sheep, the maximal mean plasma concentration of 19.5 µg/L was reached 33.6 hours after subcutaneous administration. The area under the curve mean value over a period of 7 days after dose injection was 73.3 µg\*day/L. In non-lactating sheep, the maximal mean plasma concentration of 11.3 µg/L was reached after 26.7 hours after dose administration. The area under the curve mean value over a period of 7 days after treatment was 42.5 µg\*day/L. In goats, the maximal mean plasma concentration of 20.7 µg/L was reached 36 h after administration. The area under the curve mean value over a period of 7 days was 66.8 µg\*day/L.

#### Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range from 0.1 to 0.4 mg/kg. Eprinomectin is highly bound (greater than 99%) to plasma proteins.

#### Metabolism

Eprinomectin is not extensively metabolised. Metabolites amount to approximately 10% of the total residues in plasma, milk, edible tissues and faeces.

#### Elimination

In cattle, eprinomectin is eliminated with a half-life of 65-75 h and the major route of elimination is via faeces.

In sheep, eprinomectin is eliminated with a comparable half-life of 62-78 h.  
In goats, eprinomectin is eliminated with a half-life of 91 hours.

### **Environmental properties**

Like other macrocyclic lactones, eprinomectin has the potential to adversely affect non-target organisms. Following treatment, excretion of potentially toxic levels of eprinomectin may take place over a period of several weeks. Faeces containing eprinomectin excreted onto pasture by treated animals may reduce the abundance of dung feeding organisms which may impact on the dung degradation. Eprinomectin is very toxic to dung fauna and aquatic organisms, is persistent in soils and may accumulate in sediments.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.  
Shelf life after first opening the immediate packaging: 6 months.

### **5.3 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **5.4 Nature and composition of immediate packaging**

Amber multilayer plastic vials (polypropylene / ethylene vinyl alcohol / polypropylene) with bromobutyl rubber stoppers and aluminium caps and plastic flip-off discs in a cardboard box.

#### **Pack sizes:**

50 ml vial  
100 ml vial  
250 ml vial  
500 ml vial

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as Eprinomectin may be dangerous for fish and other aquatic organisms. Do not contaminate ponds, waterways or ditches with the veterinary medicinal product or empty container.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Ceva Animal Health Ltd

**7. MARKETING AUTHORISATION NUMBER**

Vm 15052/3009

**8. DATE OF FIRST AUTHORISATION**

23 September 2015

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

November 2023

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

Approved 06 November 2023

A handwritten signature in black ink, appearing to read "Hunter.", is positioned below the approval date.